IRIDEX Expands ENT Laser Applications

August 31, 2011

New XP Module(TM) Option available for the IQ 532(TM) Green Laser for Otolaryngology and Ophthalmology

MOUNTAIN VIEW, Calif., Aug. 31, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) announced the introduction of its new XP Module - a high power factory installed option for the IRIDEX IQ 532 green laser system. The IQ 532 XP is a multifunctional device that can be utilized by both ear, nose and throat (ENT) surgeons and ophthalmologists - expanding overall utilization and making a laser investment more attractive.

The optional XP module doubles the power of the standard IRIDEX IQ 532, facilitating the rapid and efficient treatment of tissue while limiting unwanted thermal effects and provides ENT surgeons with a portable KTP 532 nm laser system that is optimized for their clinical needs.

"We developed the XP module in response to the growing demand from ENT surgeons for higher power output, particularly for use when treating laryngeal pathologies," commented Theodore A. Boutacoff, President & CEO. "When used with our family of ENT probes, physicians are now able to expand their treatment capabilities and achieve clinically effective results in less time. The IQ 532 with the XP Module and the IRIDEX family of ENT probes are optimized for the treatment of soft tissue/vascular lesions of the airway and larynx, including polyps and adhesions."

The addition of the XP Module and FlexFiber delivery devices to our existing ENT product line provides additional sales opportunities and demonstrates IRIDEX's dedication to providing physicians with innovative tools to enhance surgical procedures while improving patient and clinical outcomes.

About IQ 532 with XP Module

Our IQ 532 products are small, portable, depot serviced, and efficient solid state semiconductor-based laser systems. Some notable features include a modern touch screen user interface, wireless foot switch control, and voice confirmation. System setup is quick and easy. With the incorporation of the XP module, the IQ 532 offers significantly higher laser power capabilities for ENT, while retaining all of the user interface features and device compatibility of our standard IQ 532 product.

About ENT Delivery Devices

FlexFiber laser probes are a family of single-use, laser delivery devices available in a range of fiber diameters. Compatible with all common flexible scopes, they are used for laser delivery during laryngeal surgeries and are intended for the treatment of soft tissue/vascular lesions of the airway and larynx, including polyps and adhesions. IRIDEX's family of OtoProbe(TM) delivery devices are used for laser delivery during otologic surgeries and are indicated for, but not limited to, incision, excision, coagulation, and vaporization of soft and fibrous tissue, including osseous tissue.

About IRIDEX Corporation

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's sales opportunities, growth initiatives and new products. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and our Quarterly Reports on Form 10-Q for the quarters ended April 2, 2011 and July 2, 2011, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SOURCE IRIDEX Corporation